Castle Biosciences
$64.799876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$64.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$6.18 (-8.71%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell CSTL and other stocks, options, and ETFs commission-free!
About CSTL
Castle Biosciences, Inc. Common Stock, also called Castle Biosciences, is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX. The listed name for CSTL is Castle Biosciences, Inc. Common Stock.
CEO
Derek J. Maetzold
Employees
133
Headquarters
Friendswood, Texas
Founded
2007
Market Cap
1.71B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
272.39K
High Today
$70.72
Low Today
$63.69
Open Price
$70.10
Volume
473.20K
52 Week High
$84.00
52 Week Low
$21.01
Collections
CSTL Earnings
-$1.05
-$0.66
-$0.28
$0.11
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, After Hours